samedan logo
 
 
spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

CrystecPharma win CPhI Excellence in Pharma Award for Contract Services and Outsourcing

Crystec are delighted to have been awarded the CPhI Excellence in Pharma Award for Contract Services and Outsourcing

The award was presented for Crystec’s modified supercritical anti-solvent (mSAS) technology for accelerated product development, and chosen from shortlisted companies including 3M, Alcami, Catalent Pharma Services and Merck.

The winners of the CPhI Awards were announced on Tuesday 24th October during an awards gala in Frankfurt, Germany. Crystec’s CEO, Paul Thorning, said of the prestigious award: “It is our great pleasure to have been recognised for our work across the industry through our expertise in crystallisation and particle engineering. Our mSAS technology platform has the potential, not only to add value to product development programmes through improving the performance of medicines, but to streamline product development, reduce manufacturing costs and accelerate the route to market. We are very proud of our company and of the solutions that we provide for our clients, as well as our own development programmes. We are particularly honoured to have won this award in the company of such renowned organisations.”

For more information about Crystec’s mSAS technology, please contact Emily Bevis (emily.bevis@crystecpharma.com).

About CPhI
The International Convention on Pharmaceutical Ingredients and Intermediates (CPhI) hold several events each year aimed at bringing together people from across the pharmaceutical supply chain. CPhI Worldwide is the largest and most diverse gathering of pharmaceutical professionals in the world. With over 42,000 visiting professionals and more than 2500 exhibitors from 153 countries, there is no better platform to explore new business opportunities.

About CPhI Awards
Established in 2004, the CPhI Pharma Awards are among the most prestigious recognitions within the Pharmaceutical industry. The Awards celebrates thinkers and creators breaking new ground and strongly advocates companies committed to driving the industry forward.


About Crystec
CrystecPharma is a pharmaceutical crystal and particle engineering company, applying supercritical fluid technology to improve the performance of medicines. The company has a strong research and development base, in both the UK and China. Crystec supports pharmaceutical companies to optimise the development of their own products, typically through improving bioavailability, stability or changing routes of administration. The company also applies the strength of its technology to develop its own supergeneric products. Crystec is a young, dynamic company, with a passion for ensuring that strong science benefits human health. For more information, please visit www.crystecpharma.com.

Crystec Ltd.
Norcroft Building
Richmond Road
Bradford, United Kingdom
BD7 1DP

T: +44 1274 235592
E: info@crystecpharma.com
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Nemera organized an expert review on the present and future of inhalation products

“Connectivity in every new inhalation device?” This topic was one of those discussed with different inhalation experts - Manfred Keller, Pascal Cavaillon and Henry Chrystyn – during a round table organized by Nemera in Paris to review the advantages and limitations of inhalation devices.
More info >>


White Papers

The EC Definition of a Nanomaterial - Potential Measurement Methodologies

NanoSight

In October 2011 the European Commission published a definition of Nanomaterials. This move followed more than six years of scientific consideration of the potential toxicological and environmental challenges posed by engineered nanomaterials.
More info >>

Industry Events

BioTrinity 2019

30 April - 1 May 2019, etc.venues 155 Bishopsgate, London EC2M 3YD

BioTrinity 2019 is taking place from the 30th April – 1stMay at etc.venues 155 Bishopsgatein London. Now in its 13th year, BioTrinity remains the leading Life Sciences Biopartnering and Investment conference in Europe, and generates unrivalled opportunities for life science companies, academics, investors, and major pharmaceutical players to come together to do deals and establish collaborations.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement